Recombinant human epoetin beta in the treatment of renal anemia

References

• AbrahamPAMacresMGBlood pressure in hemodialysis patients during amelioration of anemia with erythropoietinJ Am Soc Nephrol19912927361751794
   PubMed Web of Science ®Google Scholar
• AlbetazziADi LiberatoLDanieleFEfficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients:results of a multicenter studyInt J Artif Organs19982112189554820
   PubMed Web of Science ®Google Scholar
• AnandISChandrashekharYFerrariRPathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormonesBr Heart J199370357628217445
   PubMedGoogle Scholar
• AstorBCMuntnerPLevinAAssociation of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994)Arch Intern Med20021621401812076240
   PubMed Web of Science ®Google Scholar
• BennettWMA multicenter clinical trial of epoetin beta for anemia of end-stage renal diseaseJ Am Soc Nephrol1991199081883969
   PubMed Web of Science ®Google Scholar
• BennettCLLuminariSNissensonARPure red-cell aplasia and epoetin therapyN Engl J Med20043511403815459301
   PubMed Web of Science ®Google Scholar
• BesarabABoltonWKBrowneJKThe effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietinN Engl J Med1998339584909718377
   PubMed Web of Science ®Google Scholar
• BesarabAFlahartyKKErslevAJClinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationJ Am Soc Nephrol199221405161627763
   PubMed Web of Science ®Google Scholar
• BesarabAReyesCMHornbergerJMeta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patientsAm J Kidney Dis2002404394612200793
   PubMed Web of Science ®Google Scholar
• BommerJKugelMSchoeppeWDose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal diseaseContrib Nephrol19986685933292151
   PubMedGoogle Scholar
• CasadevallNNatafJVironBPure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietinN Engl J Med20023464697511844847
   PubMed Web of Science ®Google Scholar
• CollinsAJKasiskeBHerzogCThe United States Renal Data System 2004 annual data reportAm J Kidney Dis200545Suppl 1
   Web of Science ®Google Scholar
• CollinsAJLiSSt PeterWDeath, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%J Am Soc Nephrol20011224657311675424
   PubMed Web of Science ®Google Scholar
• EschbachJWEgrieJCDowningMRCorrection of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trialN Engl J Med19873167383537801
   PubMed Web of Science ®Google Scholar
• FoleyRNMurrayAMLiSChronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999J Am Soc Nephrol2005164899515590763
   PubMed Web of Science ®Google Scholar
• FoleyRNParfreyPSHarnettJDThe impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal diseaseAm J Kidney Dis19962853618712222
   PubMed Web of Science ®Google Scholar
• FoleyRNParfreyPSMorganJEffect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathyKidney Int20005813253510972697
   PubMed Web of Science ®Google Scholar
• FoleyRNParfreyPSSarnakMJClinical epidemiology of cardiovascular disease in chronic renal diseaseAm J Kidney Dis199832Suppl 3S112199820470
   PubMed Web of Science ®Google Scholar
• FrankHHeusserKHoffkenBEffect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patientsKidney Int2004668324015253740
   PubMed Web of Science ®Google Scholar
• FrifeltJJTvedegaardEBruunKEfficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weeklyPerit Dial Int19961659488981527
   PubMed Web of Science ®Google Scholar
• FurulandHLindeTAhlmenJA randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patientsNephrol Dial Transplant2003183536112543892
   PubMed Web of Science ®Google Scholar
• GrzeszczakWSulowiczWRutkowskiBThe efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta is effective in peritoneal dialysis patients with chronic renal anaemiaNephrol Dial Transplant2005209364415769814
   PubMed Web of Science ®Google Scholar
• HalstensonCEMacresMKatsSaComparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin betaClin Pharmacol Ther199150702121752115
   PubMed Web of Science ®Google Scholar
• HarnettJDKentGMFoleyRNCardiac function and hematocrit levelAm J Kidney Dis199525Suppl 1S377702071
   PubMed Web of Science ®Google Scholar
• HayashiTSuzukiAShojiTCardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failureAm J Kidney Dis200035250610676724
   PubMed Web of Science ®Google Scholar
• HynesDMStroupeKTGreerJWPotential cost savings of erythropoietin administration in end-stage renal diseaseAm J Med20021121697511893342
   PubMed Web of Science ®Google Scholar
• JungersPChoukrounGOualimZBeneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patientsNephrol Dial Transplant2001163071211158405
   PubMed Web of Science ®Google Scholar
• KaizuKUriuKEtoSEffects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failureJapan J Nephrol19933598997
   Google Scholar
• KaufmanJSRedaDJFyeCLSubcutaneous compared with intravenous epoetin in patients receiving hemodialysisN Engl J Med1998339578839718376
   PubMed Web of Science ®Google Scholar
• KaupkeCJVaziriNDSampsonJREffect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patientsInt J Artif Organs199013218222373550
   PubMed Web of Science ®Google Scholar
• KDOQI; National Kidney FoundationKDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney diseaseAm J Kidney Dis200647Suppl 3S1114516678659
   PubMed Web of Science ®Google Scholar
• KeithDSNicholsGAGullionCMLongitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organizationArch Intern Med20041646596315037495
   PubMed Web of Science ®Google Scholar
• KleophasWKultJKreusserWon behalf of the Collaborative Study GroupTolerability and efficacy of multidose epoetin beta (Reco-Pen®) for subcutaneous administration in patients with anemia due to renal failureKidney Blood Press Res200326192812886047
   PubMed Web of Science ®Google Scholar
• KochKMKoeneRAMessingerDThe use of epoetin beta in anemic predialysis patients with chronic renal failureClin Nephrol19954420188556837
   PubMed Web of Science ®Google Scholar
• KovesdyCPTrivediBKKalantar-ZadehKAssociation of anemia with outcomes in men with moderate and severe chronic kidney diseaseKidney Int200669560416395253
   PubMed Web of Science ®Google Scholar
• KuriyamaSTomonaryHYoshidaHReversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patientsNephron199777176859346384
   PubMed Web of Science ®Google Scholar
• LevinAPrevalence of cardiovascular damage in early renal diseaseNephrol Dial Transplant200116Suppl 2711
   Web of Science ®Google Scholar
• LevinAThe role of anemia in the genesis of cardiac abnormalities in patients with chronic kidney diseaseNephrol Dial Transplant2002172071011812866
   PubMed Web of Science ®Google Scholar
• LevinADjurdjevODuncanJHaemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomesNephrol Dial Transplant200621370716249203
   PubMed Web of Science ®Google Scholar
• LevinADjurdjevOThompsonCCanadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKDAm J Kidney Dis20054679981116253719
   PubMed Web of Science ®Google Scholar
• LevinAThompsonCREthierJLeft ventricular mass index increase in early renal disease: impact of decline in hemoglobinAm J Kidney Dis1999341253410401026
   PubMed Web of Science ®Google Scholar
• LinFKSuggsSLinCHCloning and expression of the human erythropoietin geneProc Natl Acad Sci U S A198582758043865178
   PubMed Web of Science ®Google Scholar
• LocatelliFAljamaPBaranyPEuropean Best Practice Guidelines Working GroupRevised European best practice guidelines for the management of anaemia in patients with chronic renal failureNephrol Dial Transplant200419Suppl 2ii14715206425
   PubMedGoogle Scholar
• LocatelliFAljamaPBaranyPErythropoietic proteins and antibody-mediated pure red cell aplasia: where are we now and where do we go from here?Nephrol Dial Transplant2004b192889314736947
   PubMed Web of Science ®Google Scholar
• LocatelliFBaldamusCAVillaGon behalf of the Study GroupOnce weekly compared with three-times weekly subcutaneous epoetin ²: results from a randomized, multicenter, therapeutic equivalence studyAm J Kidney Dis2002401192512087569
   PubMed Web of Science ®Google Scholar
• LocatelliFMarcelliDConteFCardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e TrapiantoNephrol Dial Transplant200015Suppl 5698011073278
   PubMed Web of Science ®Google Scholar
• LocatelliFPisoniRLCombeCAnaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrol Dial Transplant2004191213214671047
   PubMed Web of Science ®Google Scholar
• LuiSFLawCBTingSMOnce weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysisClin Nephrol199136246511752075
   PubMed Web of Science ®Google Scholar
• MaJEbbenJXiaHCollinsAHematocrit level and associated mortality in hemodialysis patientsJ Am Soc Nephrol1999106101910073612
   PubMed Web of Science ®Google Scholar
• MadoreFLowrieEGBrugnaraCAnemia in hemodialysis patients: variables affecting this outcome predictorJ Am Soc Nephrol19978192199402095
   PubMed Web of Science ®Google Scholar
• MorenoFSanz-GuajardoDLopez-GomezJMIncreasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients, Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of NephrologyJ Am Soc Nephrol2000113354210665941
   PubMed Web of Science ®Google Scholar
• NavarroJFTeruelJLMarcenRImprovement of erythropoietin-induced hypertension in hemodialysis patients changing the administration routeScand J Urol Nephrol19952911147618043
   PubMed Web of Science ®Google Scholar
• NomatoYKawaguchiYKubotaMA multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysisPerit Dial Int19941456608312416
   PubMed Web of Science ®Google Scholar
• ParfreyPSFoleyRNHarnettJDOutcome and risk factors for left ventricular disorders in chronic uraemiaNephrol Dial Transplant1996111277858672023
   PubMed Web of Science ®Google Scholar
• ParfreyPSFoleyRNWittreichBHDouble-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart diseaseJ Am Soc Nephrol2005162180915901766
   PubMed Web of Science ®Google Scholar
• PortolesJTorralboAMartinPCardiovascular effects of recombinant human erythropoietin in predialysis patientsAm J Kidney Dis19972954189100042
   PubMed Web of Science ®Google Scholar
• RegidorDLKoppleJDKovesdyCPAssociations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patientsJ Am Soc Nephrol20061711819116565261
   PubMed Web of Science ®Google Scholar
• RobinsonBMJoffeMMBernsJSAnemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over timeKidney Int20056823233016221236
   PubMed Web of Science ®Google Scholar
• RogerSDMcMahonLPClarksonAEffects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trialJ Am Soc Nephrol2004151485614694167
   PubMed Web of Science ®Google Scholar
• RossertJLevinARogerSDEffect of early correction of anemia on the progression of CKDAm J Kidney Dis2006477385016632012
   PubMed Web of Science ®Google Scholar
• RossertJMcClellanWMRogerSDEpoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?Nephrol Dial Transplant2002173596211865076
   PubMed Web of Science ®Google Scholar
• SalehAKraneNKCaballeroMOnce weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPDAdv Perit Dial19917288911680448
   PubMedGoogle Scholar
• SilverbergDOutcomes of anemia management in renal insufficiency and cardiac diseaseNephrol Dial Transplant200318Suppl 2ii7ii1212819294
   PubMedGoogle Scholar
• SinnassamyPAndreJLTreizeGEffect of treatment with human recombinant erythropoietin on the anemia of children with end-stage renal failure French multicentre studyArch Fr Pediatr19935020188338412
   PubMedGoogle Scholar
• StorringPLTipladyRJGaines DasREEpoetin alfa and beta differ in their erythropoietin isoform compositions and biological propertiesBr J Haematol199810079899450795
   PubMed Web of Science ®Google Scholar
• ThomasSRampersadMAnaemia in diabetesActa Diabetologica200441Suppl 1S131715103543
   PubMed Web of Science ®Google Scholar
• VolkovaNArabLEvidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patientsAm J Kidney Dis200647243616377382
   PubMed Web of Science ®Google Scholar
• WeissLGClyneNDivino Fihlhoon behalf of the Swedish Study GroupThe efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ²: results from a randomized controlled multicentre trialNephrol Dial Transplant20001520141911096148
   PubMed Web of Science ®Google Scholar
• WinearlsCGOliverDOPippardMJEffect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysisLancet19862117582877323
   PubMed Web of Science ®Google Scholar